AUPH vs. PRTC, PAHC, NRIX, SAGE, NUVB, WVE, COGT, PRAX, IRON, and CVAC
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include PureTech Health (PRTC), Phibro Animal Health (PAHC), Nurix Therapeutics (NRIX), Sage Therapeutics (SAGE), Nuvation Bio (NUVB), Wave Life Sciences (WVE), Cogent Biosciences (COGT), Praxis Precision Medicines (PRAX), Disc Medicine (IRON), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
PureTech Health (NASDAQ:PRTC) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
PureTech Health has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Aurinia Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 73.61%. Given PureTech Health's higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than PureTech Health.
PureTech Health has higher earnings, but lower revenue than Aurinia Pharmaceuticals.
0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aurinia Pharmaceuticals received 560 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Aurinia Pharmaceuticals and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.87 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
PureTech Health has a net margin of 0.00% compared to PureTech Health's net margin of -32.69%. Aurinia Pharmaceuticals' return on equity of 0.00% beat PureTech Health's return on equity.
Summary
Aurinia Pharmaceuticals beats PureTech Health on 9 of the 15 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
